AHA 2019

Episodes 1-16 of 18

GLP-1RA treatment effect in patients with T2DM and PAD
GLP-1RA treatment effect in patients with T2DM and PAD
AHA 2019
GLP-1RA treatment effect in patients with T2DM and PAD
- Subodh Verma, MD, PhD
Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod
Possible favorable effects of icosapent ethyl on plaque-parameters
Possible favorable effects of icosapent ethyl on plaque-parameters
AHA 2019
Possible favorable effects of icosapent ethyl on plaque-parameters
- Prof. Stephen Nicholls
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
AHA 2019
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
- Prof. Freek Verheugt, MD
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
AHA 2019
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
AHA 2019
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
- Prof. Donald Lloyd-Jones
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
AHA 2019
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
- Prof. Lynne Stevenson
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
AHA 2019
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
- Scott Solomon, MD
More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS
More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS
AHA 2019
More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS
Benefit on QoL with revascularization proportional to severity of angina symptoms
Benefit on QoL with revascularization proportional to severity of angina symptoms
AHA 2019
Benefit on QoL with revascularization proportional to severity of angina symptoms
- Prof. John Spertus
Fish oil treatment reduces several plaque parameters after 9 months
Fish oil treatment reduces several plaque parameters after 9 months
AHA 2019
Fish oil treatment reduces several plaque parameters after 9 months
- Prof. Lawrence Leiter, MD
New tool can help identify FH patients
New tool can help identify FH patients
AHA 2019
New tool can help identify FH patients
Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia
Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia
AHA 2019
Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia
- Sripal Bangalore, MD
Succesful repurposing of an old anti-inflammatory drug for a new application
Succesful repurposing of an old anti-inflammatory drug for a new application
AHA 2019
Succesful repurposing of an old anti-inflammatory drug for a new application
- Aruna Pradhan, MD
Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI
Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI
AHA 2019
Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI
- Jean-Claude Tardif, MD
Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes
Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes
AHA 2019
Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes
- John McMurray, MD

1/2

Episodes 1-16 of 18

Title

Share on ReachMD